Cytosorbents Corp 8-K Summary: Annual Meeting Results
Business Context and Reporting Period
This Form 8-K reports the results of the 2021 Annual Meeting of Stockholders held on June 1, 2021. The Company is an emerging growth company incorporated in Delaware, with its common stock (CTSO) trading on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
As of the record date (April 12, 2021), 43,314,947 shares were outstanding. A quorum was established with 29,560,235 shares represented. All four proposals submitted to stockholders were approved:
- Proposal 1 (Election of Directors): All five nominees were elected. Notably, Al W. Kraus and Alan D. Sobel received significant "Against" votes (8,411,918 and 10,455,586 respectively), though they still secured majority support.
- Proposal 2 (Say-on-Pay): Advisory approval of named executive officer compensation was granted with 16,862,382 votes "For" versus 3,803,069 "Against".
- Proposal 3 (Say-on-Pay Frequency): Stockholders voted to hold advisory compensation votes annually (1 Year), with 13,281,073 votes in favor.
- Proposal 4 (Auditor Ratification): The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified with 28,482,540 votes "For".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors. The document is limited to the procedural results of the shareholder vote.
Investor Verification Checklist
- Verify the specific reasons for the high "Against" vote count for directors Al W. Kraus and Alan D. Sobel in the proxy statement.
- Confirm the total number of shares outstanding and the percentage of shares represented at the meeting (approximately 68.2%).
- Review the full proxy statement for details on executive compensation packages approved under Proposal 2.
- Check subsequent filings for the Company's financial performance for the fiscal year ending December 31, 2021.